1stOncology™: Cancer Intelligence Service – Page 11643 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference

On May 28, 2020 Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, reported it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 9:00 a.m. EDT (Press release, Cue Biopharma, MAY 28, 2020, https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-present-corporate-overview-and-pipeline-progress [SID1234608303]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Daniel Passeri, chief executive officer, will provide an overview of the Company’s Immuno-STAT (Selective Targeting and Alteration of T cells) and Neo-STAT platforms and an update on the on-going clinical trial for its lead drug candidate CUE-101, as well as pipeline progress and anticipated corporate development milestones. A live and archived version of the webcast will be available at View Source The presentation will also be archived for 30 days on the Company’s website.

About the CUE-100 Series
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About Immuno-STAT
Immuno-STAT biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a peptide-MHC complex (pMHC) to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.

The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered directly in the patient’s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients’ T cells to be extracted, modified outside the body (ex vivo), and reinfused.

Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies

On May 28, 2020 Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., reported a strategic collaboration to apply Tavros’ functional genomic discovery platform to develop next generation targeted small molecule drug candidates, initially to expand Zentalis’ oncology pipeline (Press release, Zentalis Pharmaceuticals, MAY 28, 2020, View Source [SID1234578258]).

"We are pleased to be collaborating with Zentalis, as this aligns with Tavros’ goal to improve cancer therapy by uncovering unique and druggable vulnerabilities within tumors," remarked Tavros CEO and co-founder Eoin McDonnell on behalf of Tavros co-founders Kris Wood and Greg Mossinghoff. "The Tavros functional genomic discovery platform employs proven technologies and proprietary know-how to significantly increase clinical success, as well as to improve the tolerability and toxicity profile of a new drug."

Tavros’ strategic approach allows for an unbiased analysis of intricate cellular signaling pathways to discover novel targets, synthetic lethality pairs, mechanisms to overcome cancer resistance, and unique genetic signatures for clinical trials.

Zentalis CEO Anthony Sun commented, "Tavros and Zentalis share a common goal: to utilize proprietary technologies to discover and develop drugs that are safer, more efficacious and tolerable for patients than existing therapies. Leveraging the unique insights provided by Tavros’ technologies coupled with Zentalis’ strong medicinal chemistry expertise, we believe this relationship could yield multiple novel drug candidates and combinations that may have the potential to address unmet needs for cancer patients."

The transaction terms were structured to build and expand the Tavros discovery platform, with each company given the rights to any new products generated from the platform.

Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

On May 28, 2020 Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, reported that João Siffert, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:00 a.m. ET (Press release, Abeona Therapeutics, MAY 28, 2020, View Source [SID1234561642]).

A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com. The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days.

Invitae to Present at the William Blair 40th Annual Growth Stock Conference

On May 28, 2020 nvitae Corporation (NYSE: NVTA), a leading medical genetics company, reported that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:20 a.m. Central / 7:20 a.m. Pacific (Press release, Invitae, MAY 28, 2020, View Source [SID1234561381]).

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)

The live webcast of both the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusion of the presentation.

Ipsen appoints David Loew as Chief Executive Officer

On May 28, 2020 Ipsen reported that its Board of Directors has appointed David Loew as its new Chief Executive Officer (CEO) and as Board member (Press release, Ipsen, MAY 28, 2020, View Source [SID1234558652]). The CEO appointment will take effect on July 1st, 2020.

The Board of Directors expresses its gratitude to Aymeric Le Chatelier, who steered the group very well in an exceptionally challenging environment and who will remain in the role of acting CEO until July 1st, 2020 and will continue in his role of Chief Financial Officer.

David Loew will be based at Ipsen’s headquarters in Boulogne-Billancourt, France. His mission will be to ensure Ipsen’s continued growth and to advance its pipeline via a long-term value-adding external innovation strategy, while fostering a culture of entrepreneurship, agility and patient-centricity. David is a Swiss citizen.

Since 2016, David has been CEO of Sanofi Pasteur Vaccines. During his tenure, he piloted a successful worldwide growth strategy via acquisitions and licensing deals. He also undertook a series of transformational initiatives: developing a global pipeline, reinforcing production strategy to strengthen compliance and increase capacity and building key programs to bring the company to best-practice level in talent acquisition, medical affairs, R&D productivity and shaping the external environment.

David brings nearly thirty years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the US, European and international markets. He started his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics businesses across the EU region.

"The Board and I are delighted to welcome David Loew as Ipsen’s new CEO. David is a seasoned leader with extensive worldwide experience in business areas of key importance to Ipsen," said Marc De Garidel, Chairman of Ipsen. "I have full confidence that David will provide the leadership and expertise needed to guide the group through its next phase of growth and realize Ipsen’s vision of being a global biotechnology leader through the identification, development and commercialization of transformative and differentiated products."

"I am deeply honored by this appointment and am particularly excited to join Ipsen at this point in its history. For the past five years, the group has maintained a remarkable growth trajectory thanks to its focus on delivering innovative solutions to patients with high unmet medical needs," noted David Loew. "I look forward to working with my new colleagues and the Board so that together we can continue to develop life-improving solutions for patients."